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Ovarian cancer is the most severe disease of the female repro-
ductive tract as it is associated with the highest mortality rates.
There are 3 categories of ovarian cancer including epithelial, stro-
mal, and germ cell tumors. From these categories, epithelial and in
particular serous epithelial ovarian cancer is the most common
type.1 Treatment of the cancer depends a lot on its stage. When it is
organ conﬁned, it can be surgically removed.2 However, in the case
where it has progressed beyond the ovaries, a combination of sur-
gery and chemotherapy is needed.3 An important prognostic factor
that could predict survival is whether the tumor size is reduced after
surgery and to what extent.4 In chemotherapy, the 2 most impor-
tant drugs used in the treatment of ovarian cancer are carboplatin
and paclitaxel.5 Nowadays, one of the greatest challenges associated
with chemotherapy is the fact that cancers have started developing
resistance against such drugs, and consequently, their effectiveness
in eradicating the tumor has been signiﬁcantly reduced.6 This has
raised the need for the development of a new treatment that would
remain unaffected by these mechanisms of resistance.
Epigenetics is a ﬁeld which focuses on the study of heritable
changes which do not result from changes in the DNA sequence.
Epigenetic changes include DNA methylation, which is the addition
of a methyl group to a cytosine (C) residue with the aid of an
enzyme known as DNA methyltransferase (DNMT), and histone
modiﬁcations. These are divided into histone acetylation, deacety-
lation, and methylation events carried out by histone acetyl-
transferases, histone deacetylases (HDACs), and histone
methyltransferases (HMTs), respectively.7 Recently, research has
focused on epigenetic changes and their relation to cancer. In fact,
aberrant methylation of CpG islands which are found in close
proximity to gene transcription initiation sites and are normally
methylated has been linked to tumor initiation and progression.8
Because of their involvement in tumorigenesis, the biology of
these changes is now being investigated so that its potential in the
treatment of ovarian cancer is fully understood. This mini-reviewwill describe the common molecular mechanisms of ovarian can-
cer and discuss the prospective of epigenetic remedies in the treat-
ment of ovarian cancer.
Signaling Pathways in Ovarian Cancer
There are different classiﬁcations of epithelial ovarian cancer
whose pathogenesis occurs in a slightly different way. More specif-
ically, they are classiﬁed as type 1 and type 2 ovarian tumors. Type 1
tumors, including endometrioid, mucinous, and low-grade serous,
are developing at a slow pace, whereas type 2 tumors progress to
high-grade serous carcinomas at a rapid pace.9,10 Expression proﬁling
studies have shown that these 2 types of cancer cluster separately and
are therefore characterized by different molecular pathways. P53
mutations are important events in the development of high-grade
carcinomas, whereas mutations in KRAS, BRAF, phosphatase and
tensin homolog (PTEN), and b-catenin are associated with low-grade
tumors11 (Figure 1A and B, respectively). High-grade tumors are
associated with genomic instability, aggressive clinical appearance,
and mortality resulting from ovarian cancer.12
DNA Methylation in Ovarian Cancer
DNA methylation is a process during which a methyl group is
added to a cytosine nucleotide with the aid of a DNA methyl-
transferase enzyme. DNA methylation events occur normally in cells
and appear to be of repressive nature.13 Thériault et al.14 suggest that
hypomethylation of the promoter region of KF14, a gene encoding a
mitotic kinase which is known as an important oncogene in cancer,
could explain its overexpression in ovarian cancer. Moreover, they
describe a variety of approaches on the upregulation of the gene, and
these could be important therapeutic targets. CpG island promoter
hypermethylation in BRCA1 and BRCA2 genes was found to be
associated with increased sensitivity to some chemotherapeutic
agents.15 These genes are frequently mutated in breast, ovarian, and
other cancers, and tumors that contain these mutations are more
sensitive to chemotherapeutic agents. The sensitivity resulting from
epigenetic regulation of the genes was comparable to that resulting
from germline mutations in the genes.15 Tumor suppressor candidate
3 (TUSC3) is another gene that is epigenetically silenced by aberrant
methylation of its promoter in ovarian cancer, and it has been sug-
gested that it could act as a prognostic factor for this cancer.16Clinical Ovarian and Other Gynecologic Cancer Month 2015 - 1
Figure 1 Schematic Diagram Depicting the Types of Ovarian Cancer. (A) The Molecular Pathway That Leads to High-Grade Serous
Carcinoma (Type 2 Tumors). (B) The Molecular Pathway That Leads to Low-Grade Serous, Endometrioid, and Mucinous
Ovarian Cancer (Type 1 Tumors)
Types of Ovarian Cancer
2 - CliEpigenetic regulation of all these genes should be further investigated
as it could potentially be exploited to produce artiﬁcial targets that
silence oncogenes. In fact, this is the case for the epithelial cell
adhesion molecule (EpCAM) which is overexpressed in ovarian
cancer and in other cancers as well. Nunna et al.17 achieved targeted
methylation of the promoter of the gene, and this resulted in
reduction in the expression of the gene, a mechanism which is very
promising for cancer treatment.
Histone Modiﬁcations in Ovarian Cancer
Histone modiﬁcations are changes that affect the protruding tails
of histone proteins which are important for the packaging of the
DNA in nucleosomes. These modiﬁcations can be associated with
active or silent chromatin and occur normally in cells.18 Lysine
acetylation of histone 3 and 4 tails is associated with active chro-
matin (euchromatin), whereas lysine 9 methylation of histone 3 is
associated with inactive chromatin (heterochromatin).19,20 Expres-
sion of trimethylation of histone 3 at lysine 27 (H3K27me3) has
been suggested to be a useful factor for the prognosis of ovarian
cancer as lower expression is associated with lower survival.
Methylation is carried out by the enhancer of zeste 2 (EZH2)
complex which is abundantly expressed in many cancers.21 Histone
hypoacetylation and aberrant promoter methylation are 2 events
that have been associated with the low levels of the deleted in lung
and esophageal cancer 1 (DLEC1) gene in ovarian cancer cell lines.22
DLEC1 is a gene which is believed to have tumor suppressor activity
in other cancers including lung and renal cancers.23 Therefore, it isnical Ovarian and Other Gynecologic Cancer Month 2015very important that the gene is further studied as it could serve as a
diagnostic biomarker for not only ovarian but also other cancer
types in the future. Furthermore, a family of transcription factor
genes which are silenced because of histone modiﬁcations is those
encoding members of the GATA family of transcription factors
which—as their name suggests—bind to the nucleotide sequence
“GATA.”24 The silencing of these transcription factors is achieved
by histone 3 and 4 hypoacetylation and trimethylation loss at lysine
4 of histone 3 which is in the vicinity of the promoter of the genes.
The outcome of the “GATA” silencing is the loss of a tumor sup-
pressor gene which is known as Disabled-2.24 Therefore, this event
promotes ovarian carcinogenesis.
The biology of epigenetic changes is of growing research interest
to many cancer research centers around the world because there is
vast potential for genes whose expression is epigenetically modiﬁed
to serve as biomarkers or therapeutic targets in cancer. The proteins
that carry out these modiﬁcations are of great interest as well.
HDAC inhibitors, which as their name suggests inhibit the deace-
tylation of histones, are very promising anticancer agents.25 Beli-
nostat (also known as PXD101; a small-molecule hydroxamate-type
inhibitor of class I, II, and IV HDAC enzymes) is an example of
such an inhibitor, which achieves antitumor activity in ovarian
cancer, and its action can be enhanced by the use of carboplatin.26
Acetylation is associated with active chromatin and hence gene
expression. Therefore, deacetylase inhibitors in this case maintain
the expression of tumor suppressor genes which are normally
silenced in cancer.
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Noncoding RNAs (ncRNAs) are RNA molecules that are tran-
scribed but not translated and, therefore, they play a regulatory role
in the cell. Such molecules include microRNAs (miRNAs, miR),
small interfering RNAs (siRNAs), small nuclear RNAs (snRNAs),
long ncRNAs, and Piwi-interacting RNAs (piRNAs) among
others.27 Their abundance can be epigenetically altered, and this can
inﬂuence the expression of certain genes they control. A long ncRNA
was found to be epigenetically silenced in type 2 epithelial ovarian
cancer. More speciﬁcally, it had been previously identiﬁed that the
CpG island of the promoter of the gene encoding the long ncRNA
was methylated and silenced in ovarian cancer tissues. Loss of this
long ncRNA results in reduced proliferation and colony formation.
This long ncRNA seems to have a role in cell polarity regulation;
therefore, these ﬁndings have important implications for metastasis
in ovarian cancer.28 In another study, hypermethylation of the
promoter region of the gene encoding miRNA-199b-5p resulted in
its silencing. This event was found to be associated with chemo-
resistance in ovarian cancer.29 Therefore, exploring the biology of
this miRNA could produce important ﬁndings for the prevention of
this chemoresistance. Xiang et al.30 identiﬁed 2 miRNAs, miR-152
and miR-185 which are signiﬁcantly downregulated in ovarian cell
lines that are resistant to cisplatin through an epigenetic mechanism.
From further experimentation, they concluded that these miRNAs
are involved in cisplatin sensitivity. miRNAs should be further
investigated as they could potentially serve as epigenetic markers not
only in ovarian but also in other cancers.
Conclusion
Epigenetic changes play a key role in the regulation of several
genes in ovarian cancer. Understanding the mechanisms under-
pinning these changes is essential because it would contribute to the
development of novel therapeutic targets with improved efﬁcacy.
Additionally, it could also contribute to the development of bio-
markers and biomarker panels that may serve as prognostic, pre-
dictive, and/or diagnostic tools in ovarian cancer.Disclosure
The authors disclose that there are no actual or potential conﬂicts
of interest including any ﬁnancial, personal, or other relationships
with other people or organizations within that could inappropriately
inﬂuence (bias) the work.
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